Clinical Trial Detail

NCT ID NCT03602859
Title A Phase 3 Comparison of Platinum-Based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-Line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer (FIRST)
Recruitment Recruiting
Gender female
Phase Phase III
Variant Requirements No
Sponsors Tesaro, Inc.
Indications

ovarian clear cell adenocarcinoma

ovarian serous carcinoma

ovarian seromucinous carcinoma

ovarian endometrial cancer

ovarian carcinosarcoma

Therapies

Dostarlimab + Niraparib

Niraparib

Age Groups: adult senior

No variant requirements are available.